Cytokinetics is a clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases. In 2011, with cash balances and program visibility low, Deerfield increased it’s already healthy equity position by providing Cytokinetics with $20 million in a structured equity investment.